Vol 3, No 3 (September 01, 2014): Chinese Clinical Oncology (Systemic Treatment of Cutaneous and Mucosal Melanoma - Guest Editors: Sanjiv S. Agarwala, Jun Guo, Antonio C. Buzaid)1

Review Article

Melanoma adjuvant therapy
Prashanth M. Thalanayar, Sanjiv S. Agarwala, Ahmad A. Tarhini
Genotyping of cutaneous melanoma
Isabella C. Glitza, Michael A. Davies
Treatment of BRAF-mutated advanced cutaneous melanoma
Van Anh Trinh, Yan You, Wen-Jen Hwu
BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management
Elisabeth Livingstone, Lisa Zimmer, Julia Vaubel, Dirk Schadendorf
Checkpoint inhibitors in the treatment of cutaneous malignant melanoma
Jose Lutzky
Toxicity of checkpoint inhibitors
Rafael Aron Schmerling
Algorithm for the management of metastatic cutaneous melanoma
Antonio C. Buzaid, Sanjiv S. Agarwala, Axel Hauschild, Michael Atkins
Adjuvant therapy of mucosal melanoma
Bin Lian, Jun Guo
Genotyping of mucosal melanoma
Lu Si, Xuan Wang, Jun Guo
Treatment of KIT-mutated metastatic mucosal melanoma
Kevin B. Kim, Anas Alrwas
Chemotherapy, biochemotherapy and anti-VEGF therapy in metastatic mucosal melanoma
Chuanliang Cui, Bixia Tang, Jun Guo
Checkpoint inhibitors in treatment of metastatic mucosal melanoma
Bin Lian, Jun Guo
Treatment algorithm of metastatic mucosal melanoma
Xuan Wang, Lu Si, Jun Guo

Disclosure:

1. The focused issue “Systemic Treatment of Cutaneous and Mucosal Melanoma” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Sanjiv S. Agarwala, Jun Guo and Antonio C. Buzaid served as the unpaid Guest Editors for the focused issue.

2. The series “Statistics in Oncology Clinical Trials” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Daniel J. Sargent and Qian Shi served as the unpaid Guest Editors for the series.